
CLAIMS

1. A compound according to formula (I)




(I)

wherein


A is selected from the group consisting of phenyl, thiophenyl, benzothiophenyl or benzofuranyl, unsubstituted or substituted with one, two or three members of the group R^3 consisting of halogen, C_{1-4}-alkyl, C_{1-4}-fluoroalkyl, C_{3-4}-cycloalkyl, C_{3-4}-cyclofluoroalkyl, O-C_{1-4}-alkyl, O-cyclopropyl and NC-;

or


A is selected from the group consisting of



,



and



;

R^1 is selected from the group consisting of C_{1-4}-alkyl, C_{1-4}-fluoroalkyl, C_{3-6}-cycloalkyl, R^4-$(H_2C)_m$- and R^5-$(H_2C)_n$-;

wherein

m is 1 or 2;

n is 2;

R^4 is C_{3-6}-cycloalkyl;

R^5 is -O-C_{1-4}-alkyl or -O-C_{1-4}-fluoroalkyl ;

R^2 is selected from the group consisting of H, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-cyclofluoroalkyl, HO-C_{1-4}-alkyl-, C_{1-4}-fluoroalkyl, R^6-$(H_2C)_p$-, R^7-$(H_2C)_q$-, R^6-$(H(R^9)C)_p$- and R^7-$(H(R^{10})C)_q$-;

wherein

p is 1 or 2;

q is 2;

R^6 is selected from the group consisting of HO-C_{1-2}-alkyl-, C_{3-6}-cycloalkyl, C-morpholinyl, C-imidazolyl and C-pyrazolyl;

wherein said C-pyrazolyl, C-imidazolyl and C-morpholinyl is unsubstituted or substituted with C_{1-4}-alkyl or C_{1-4}-fluoroalkyl;

R^7 is selected from the group consisting of C_{1-4}-alkyl-O-, C_{1-4}-fluoroalkyl-O-, C_{1-4}-alkyl-$S(O)_2$-, N-morpholinyl, N-imidazolyl and N-pyrazolyl;


wherein said N-pyrazolyl, N-imidazolyl, N-morpholinyl is unsubstituted or substituted with C_{1-4}-alkyl or C_{1-4}-fluoroalkyl;

R^8 and R^9 are independently selected from H or C_{1-4}-alkyl.

2. The compound of formula (I) according to claim 1, wherein A is selected from the group consisting of phenyl, thiophenyl, benzothiophenyl or benzofuranyl, unsubstituted or substituted with one or two members of the group R^3 consisting of Cl, F, Br, H_3C, H_3C-O- and NC-;


or


A is





.


3. The compound of formula (I) according to claim 1, wherein A is selected from the group consisting of


,


,


,



and


,

unsubstituted or substituted with one or two members of the group R^3 consisting of Cl, F, Br, H_3C, H_3C-O- and NC-,

or

A is


.

4. The compound of formula (I) according to any of claims 1 to 3, wherein R^1 is selected from the group consisting of C_{1-4}-alkyl, C_{3-6}-cycloalkyl, R^4-$(H_2C)_m$- and R^5-$(H_2C)_n$-; wherein

m is 1;

n is 2;

R^4 is C_{3-6}-cycloalkyl; and

R^5 is -O-C_{1-4}-alkyl.

5. The compound of formula (I) according to any of claims 1 to 3, wherein R^1 is selected from the group consisting of C_{1-4}-alkyl, C_{3-4}-cycloalkyl, R^4-$(H_2C)_m$- and R^5-$(H_2C)_n$-;
wherein
m is 1;
n is 2;
R^4 is C_{3-4}-cycloalkyl; and
R^5 is -O-C_{1-4}-alkyl.

6. The compound of formula (I) according to any of claims 1 to 5, wherein R^2 is selected from the group consisting of H, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, HO-C_{1-4}-alkyl-, C_{1-4}-fluoroalkyl, R^6-$(H_2C)_p$- and R^7-$(H_2C)_q$-;
wherein
p is 1;
q is 2;
R^6 is selected from the group consisting of C_{3-6}-cycloalkyl, C-morpholinyl, C-imidazolyl and C-pyrazolyl;
wherein said C-pyrazolyl, C-imidazolyl and C-morpholinyl is unsubstituted or substituted with C_{1-4}-alkyl.
R^7 is selected from the group consisting of -O-C_{1-4}-alkyl, -O-C_{1-4}-fluoroalkyl, C_{1-4}-alkyl-$S(O)_2$-, N-morpholinyl, N-imidazolyl and N-pyrazolyl;
wherein said N-pyrazolyl, N-imidazolyl, N-morpholinyl is unsubstituted or substituted with C_{1-4}-alkyl.

7. The compound of formula (I) according to any of claims 1 to 5, wherein R^2 is selected from the group consisting of H, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, HO-C_{1-4}-alkyl-, C_{1-2}-fluoroalkyl, R^6-$(H_2C)_p$- and R^7-$(H_2C)_q$-;
wherein
p is 1;
q is 2;
R^6 is selected from the group consisting of C_{3-6}-cycloalkyl, C-morpholinyl, C-imidazolyl and C-pyrazolyl;

wherein said C-pyrazolyl, C-imidazolyl and C-morpholinyl is unsubstituted or substituted with H_3C;

R^7 is selected from the group consisting of H_3C-O, -O-fluoromethyl, H_3C-$S(O)_2$-, N-morpholinyl, N-imidazolyl and N-pyrazolyl;

wherein said N-pyrazolyl, N-imidazolyl, N-morpholinyl is unsubstituted or substituted with H_3C.


8. The compound of formula (I) according to any of claims 1 to 5, wherein R^2 is selected from the group consisting of H, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, HO-C_{1-4}-alkyl-, C_{1-2}-fluoroalkyl, R^6-$(H_2C)_p$- and R^7-$(H_2C)_q$-;

wherein


p is 1;

q is 2;

R^6 is selected from the group consisting of C_{3-6}-cycloalkyl,




and




;


R^7 is selected from the group consisting of H_3C-O, -O-fluoromethyl, H_3C-$S(O)_2$-,



,




and




.


9. The compound of formula (I) according to any of claims 1 to 3, selected from the group consisting of




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




and




.


10. The compound of formula (I) according to claim 1, selected from the group consisting of




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,


O
N
N
N
N
N
O
OH
Cl
O
NH2


,


O
N
N
N
N
N
O
OH
Cl
O
NH2


,


O
N
N
N
N
N
O
OH
Cl
O
NH2


,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




and




.

11. The compound of formula




.

12. The compound of formula




.

13. The compound of formula




.

14. The compound of formula




.

15. The compound of formula




.

16. The compound of formula




.

17. The compound of formula




.

18. The compound of formula




.

19. The compound of formula



.

20. The compound of formula



.

21. A salt, particularly a pharmaceutically acceptable salt, of a compound according to any one of claims 1 to 20.

22. A pharmaceutical composition comprising at least one compound of formula I according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

23. The compound of formula (I) according to one or more of claims 1 to 20, or a pharmaceutically acceptable salt thereof, for use as a medicament.

24. The compound according to any of claims 1 to 20, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of inflammatory airway diseases or fibrotic diseases or cough.

25. The compound according to any of claims 1 to 20, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of idiopathic lung disease (IPF) or cough.

26. Use of the compound according to any of claims 1 to 20, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of inflammatory airway diseases or fibrotic diseases or cough.

27. Use of the compound according to any of claims 1 to 20, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of idiopathic lung disease (IPF) or cough.